By targeting key vulnerabilities, such as the system xCT–GSH–GPX4 axis, ferritinophagy, ACSL4 activity, and EBV-driven antioxidant programs, novel strategies may be developed to overcome resistance and improve patient outcomes in NPC. The gene discussed is ACSL4; the disease is nasopharyngeal carcinoma.